Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Tremelimumab Following Radioembolization in Unresectable Locally Advanced Hepatocellular Carcinoma
NCT04605731Phase 1Active, not recruiting
- Sponsor
- City of Hope
- Start
- Aug 2021
- Primary completion
- Feb 2027
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of durvalumab and tremelimumab in hepatocellular carcinoma (HCC), sponsored by City of Hope. Primary endpoints: Incidence of adverse events, Dose-limiting toxicity at 4 weeks and 1 more. Started Aug 2021; status: active, not recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04605731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04605731.